The Sub-Radar Shakeup: AI Acquisitions, Navy Contracts, and Biotech Overhauls

I'm told that several under-the-radar market players are pushing through massive operational overhauls. While the broader market focuses on mega-caps, this cohort of small-cap and niche innovators—from specialized biotechs to advanced energy providers—is quietly executing critical acquisitions and securing government contracts before the end of 2026.

Progress Software (PRGS.US)

Progress Software has been outperforming its sector recently, fueled by an aggressive expansion strategy. I'm told that the company's move to acquire Domo's AI and data platform business for USD 400 million in cash is seen internally as a major step forward. The deal is expected to close later this year, bringing over 2,400 enterprise customers into Progress's ecosystem. According to people familiar with the matter, this will significantly bolster their 2026 revenue trajectory, which management expects to reach the USD 1 billion mark.

Sangamo Therapeutics (SGMOQ.US)

Sangamo has seen notable volatility this year. The genomic medicine company is currently exploring strategic alternatives to maximize shareholder value. I've learned that their recent licensing agreement with Genentech, which brings in a USD 50 million upfront payment, is just the first step in a broader restructuring effort. They are also actively pushing their Fabry disease gene therapy toward an FDA biological license application later this year.

Hyliion Holdings (HYLN.US)

Hyliion's stock has shown signs of recovery lately. The company has fully transitioned from electric powertrains to power generation, and the shift is taking hold. According to internal sources, their newly awarded USD 41.7 million contract with the U.S. Navy for KARNO power modules is considered a landmark milestone since pivoting. This multi-megawatt expansion project is expected to scale up rapidly ahead of the next fiscal year.

Corcept Therapeutics (CORT.US)

Corcept shares have trended upward this year. The company posted a strong 32% year-over-year revenue jump to USD 256.1 million in Q2 2026. I'm told that executives are highly optimistic about the recent NDA resubmission for relacorilant, with an FDA target action date set for December 2026. If approved, this could represent a massive shakeup in their commercial pipeline.

Capstone Green Energy (TEUP.US)

Capstone has been gaining momentum in the microturbine market. Recent reports indicate a 33% revenue surge in Q3 of fiscal 2026, alongside their second consecutive quarter of positive net income. People familiar with the company's "Three Pillar" strategy suggest that this margin expansion is setting the stage for broader data center applications later this year.

Vital Farms (VITL.US)

Vital Farms continues to outpace traditional agriculture stocks. The ethical food brand is rapidly expanding its footprint, now reaching over 24,000 stores. I'm told their new egg-washing facility in Seymour, Indiana, which broke ground recently, is a critical piece of their aggressive plan to hit USD 2 billion in revenue by 2030.

Nephros (NEPH.US)

Nephros has enjoyed a solid run over the past quarter. Following its addition to the Russell Microcap Index this summer, the water filtration company reported a 36% jump in Q2 2026 net revenue to USD 6 million. I've heard that their recent pivot toward tackling emerging microplastic risks is gaining serious traction with commercial partners.

Also

• FibroBiologics (FBLG.US): The cell therapy firm recently secured a European patent for cartilage regeneration and raised approximately USD 3 million via a private placement to fund ongoing clinical trials.
• Oil-Dri Corporation of America (ODC.US): The company is planning widespread price hikes in early fiscal 2027 to offset rising freight and packaging costs, coming off a record revenue quarter.
• T Stamp Inc. (IDAI.US): The AI-powered identity company reported a 39% bump in Q1 2026 revenue, driven largely by an amended contract with a major bank, as they shift focus heavily toward Sovereign-AI technologies.

This article does not constitute investment advice.